HK1082194A1 - 包含艾柯病毒 的組合物及其應用 - Google Patents
包含艾柯病毒 的組合物及其應用Info
- Publication number
- HK1082194A1 HK1082194A1 HK06103056.9A HK06103056A HK1082194A1 HK 1082194 A1 HK1082194 A1 HK 1082194A1 HK 06103056 A HK06103056 A HK 06103056A HK 1082194 A1 HK1082194 A1 HK 1082194A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- echovirus
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002953436A AU2002953436A0 (en) | 2002-12-18 | 2002-12-18 | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
PCT/AU2003/001688 WO2004054613A1 (en) | 2002-12-18 | 2003-12-18 | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1082194A1 true HK1082194A1 (zh) | 2006-06-02 |
Family
ID=30004521
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06103056.9A HK1082194A1 (zh) | 2002-12-18 | 2006-03-09 | 包含艾柯病毒 的組合物及其應用 |
HK11112125.0A HK1157657A1 (en) | 2002-12-18 | 2011-11-09 | A method of treating a malignancy in a subject via direct picornaviral- mediated oncolysis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112125.0A HK1157657A1 (en) | 2002-12-18 | 2011-11-09 | A method of treating a malignancy in a subject via direct picornaviral- mediated oncolysis |
Country Status (12)
Country | Link |
---|---|
US (2) | US7485292B2 (zh) |
EP (1) | EP1581257B1 (zh) |
JP (2) | JP2006517189A (zh) |
KR (1) | KR101171295B1 (zh) |
CN (2) | CN102166228B (zh) |
AU (1) | AU2002953436A0 (zh) |
CA (1) | CA2510227C (zh) |
ES (1) | ES2463678T3 (zh) |
HK (2) | HK1082194A1 (zh) |
NZ (1) | NZ541230A (zh) |
WO (1) | WO2004054613A1 (zh) |
ZA (1) | ZA200505389B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AU2002953436A0 (en) * | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
CA2577692C (en) | 2004-08-20 | 2014-05-06 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
CN101132798B (zh) * | 2005-01-17 | 2011-04-27 | 溶瘤病毒有限公司 | 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物 |
WO2013157648A1 (ja) | 2012-04-19 | 2013-10-24 | 国立大学法人九州大学 | 医薬組成物 |
PL2826856T3 (pl) | 2013-07-16 | 2016-06-30 | Sia Latima | Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie |
RU2682762C2 (ru) * | 2013-11-27 | 2019-03-21 | Общество С Ограниченной Ответственностью "Панацела Лабс" | Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака |
AU2015222685A1 (en) | 2014-02-27 | 2016-09-08 | Viralytics Limited | Combination method for treatment of cancer |
CN103981152B (zh) * | 2014-04-16 | 2015-01-21 | 武汉博威德生物技术有限公司 | 一种柯萨奇病毒及其制备抗肿瘤药物之应用 |
JP7114571B2 (ja) * | 2017-03-31 | 2022-08-08 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
CN109419818B (zh) * | 2017-08-24 | 2021-08-10 | 厦门大学 | 一种用于治疗肿瘤的埃可病毒 |
CN107669707A (zh) * | 2017-11-16 | 2018-02-09 | 邹罡 | 埃可病毒作为溶瘤病毒在抗肿瘤中的应用 |
KR20210093285A (ko) * | 2018-11-13 | 2021-07-27 | 온코루스, 인크. | 캡슐화된 폴리뉴클레오티드 및 사용 방법 |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54113421A (en) * | 1978-02-24 | 1979-09-05 | Fumiaki Taguchi | Large scale cultivation of virus |
US5585254A (en) | 1987-08-21 | 1996-12-17 | University Of Colorado Foundation, Inc. | Autonomous parvovirus gene delivery vehicles and expression vectors |
EP0466815A4 (en) | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
AU2252092A (en) | 1991-06-24 | 1993-01-25 | Research Foundation Of The State University Of New York, The | De novo cell-free synthesis of picornavirus |
WO1993002556A1 (en) | 1991-07-26 | 1993-02-18 | University Of Rochester | Cancer therapy utilizing malignant cells |
US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
CA2152941C (en) | 1993-02-16 | 2003-04-22 | Francis Mccormick | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
ATE236271T1 (de) | 1993-04-30 | 2003-04-15 | Wellstat Biologics Corp | Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
HUP0003911A3 (en) | 1997-10-09 | 2007-11-28 | Pro Virus | Treatment of neoplasms with viruses |
AU3001799A (en) | 1998-03-12 | 1999-09-27 | Trustees Of The University Of Pennsylvania, The | Producer cells for replication selective viruses in the treatment of malignancy |
US6060316A (en) | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
ATE402713T1 (de) | 1999-02-05 | 2008-08-15 | Arch Dev Corp | Genetisch manipulierte herpesviren zur behandlung von tumoren |
MXPA01010393A (es) | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Tratamiento de neoplasmas con virus. |
AU2005201079C1 (en) | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
DE19939095A1 (de) | 1999-08-18 | 2001-02-22 | Univ Eberhard Karls | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
CN1289098C (zh) | 1999-09-17 | 2006-12-13 | 威尔斯塔生物公司 | 溶瘤病毒 |
CA2720361A1 (en) | 1999-11-12 | 2001-05-25 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
PT1230378E (pt) | 1999-11-15 | 2007-09-17 | Onyx Pharma Inc | ''adenovírus oncolítico'' |
AU770517B2 (en) | 1999-11-25 | 2004-02-26 | Viralytics Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AUPQ425699A0 (en) * | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AU2004202292B2 (en) | 1999-11-25 | 2007-06-14 | Viralytics Limited | Method of Treating a Malignancy in a Subject |
ATE312189T1 (de) | 2000-01-21 | 2005-12-15 | Biovex Ltd | Virusstämme für die onkolytische behandlung von krebs |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
CA2409932A1 (en) | 2000-06-01 | 2001-12-06 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
CA2430495A1 (en) | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
AU2002318104A1 (en) * | 2001-01-05 | 2002-11-25 | Corixa Corporation | Microparticles and methods for delivery of recombinant viral vaccines |
WO2002087625A1 (en) | 2001-05-02 | 2002-11-07 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
AU2002307749A1 (en) | 2001-05-09 | 2002-11-25 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
CA2442648C (en) | 2001-05-11 | 2012-10-16 | Pro-Virus, Inc. | Oncolytic virus therapy |
CA2352439A1 (en) | 2001-07-17 | 2003-01-17 | Patrick W. K. Lee | Engineering oncolytic viruses |
CA2449013C (en) | 2001-07-23 | 2012-05-22 | Onyx Pharmaceuticals, Inc. | Viral mutants that selectively replicate in targeted human cancer cells |
EP1487983A4 (en) | 2002-03-01 | 2007-08-15 | Sloan Kettering Inst Cancer | PREVENTING THE REPEAT AND METASTASIS OF CANCER |
AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
AU2003223089A1 (en) | 2002-04-29 | 2003-11-17 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
CA2484398C (en) | 2002-05-09 | 2014-01-21 | Oncolytics Biotech Inc. | Method for reducing pain using oncolytic viruses |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2005002607A2 (en) | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
US20070036758A1 (en) | 2003-07-08 | 2007-02-15 | Bertram Jacobs | Mutants of vaccinia virus as oncolytic agents |
DK1668025T3 (da) | 2003-09-26 | 2014-08-25 | Novartis Ag | Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom |
KR20060131975A (ko) | 2004-03-11 | 2006-12-20 | 바이로타르그 피티와이 엘티디 | 변형된 종양 용해 바이러스 |
US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
US8080240B2 (en) | 2004-10-21 | 2011-12-20 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
-
2002
- 2002-12-18 AU AU2002953436A patent/AU2002953436A0/en not_active Abandoned
-
2003
- 2003-12-18 CN CN201110091011.1A patent/CN102166228B/zh not_active Expired - Fee Related
- 2003-12-18 ES ES03779569.7T patent/ES2463678T3/es not_active Expired - Lifetime
- 2003-12-18 CA CA2510227A patent/CA2510227C/en not_active Expired - Fee Related
- 2003-12-18 KR KR1020057011510A patent/KR101171295B1/ko active IP Right Grant
- 2003-12-18 JP JP2004559490A patent/JP2006517189A/ja active Pending
- 2003-12-18 CN CN2003801098083A patent/CN1784242B/zh not_active Expired - Fee Related
- 2003-12-18 EP EP03779569.7A patent/EP1581257B1/en not_active Expired - Lifetime
- 2003-12-18 US US10/539,219 patent/US7485292B2/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ541230A patent/NZ541230A/en not_active IP Right Cessation
- 2003-12-18 WO PCT/AU2003/001688 patent/WO2004054613A1/en active Application Filing
- 2003-12-18 ZA ZA200505389A patent/ZA200505389B/en unknown
-
2006
- 2006-03-09 HK HK06103056.9A patent/HK1082194A1/zh not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,120 patent/US20100062020A1/en not_active Abandoned
-
2011
- 2011-07-08 JP JP2011151340A patent/JP2012046489A/ja active Pending
- 2011-11-09 HK HK11112125.0A patent/HK1157657A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1581257A4 (en) | 2007-10-17 |
JP2012046489A (ja) | 2012-03-08 |
JP2006517189A (ja) | 2006-07-20 |
KR101171295B1 (ko) | 2012-08-07 |
CN1784242B (zh) | 2011-06-08 |
AU2002953436A0 (en) | 2003-01-09 |
US7485292B2 (en) | 2009-02-03 |
US20100062020A1 (en) | 2010-03-11 |
NZ541230A (en) | 2008-04-30 |
EP1581257A1 (en) | 2005-10-05 |
KR20050115859A (ko) | 2005-12-08 |
WO2004054613A1 (en) | 2004-07-01 |
CA2510227C (en) | 2015-03-31 |
CN1784242A (zh) | 2006-06-07 |
ZA200505389B (en) | 2006-09-27 |
CN102166228A (zh) | 2011-08-31 |
ES2463678T3 (es) | 2014-05-28 |
CA2510227A1 (en) | 2004-07-01 |
EP1581257B1 (en) | 2014-04-30 |
US20060134778A1 (en) | 2006-06-22 |
HK1157657A1 (en) | 2012-07-06 |
CN102166228B (zh) | 2014-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1082194A1 (zh) | 包含艾柯病毒 的組合物及其應用 | |
PT2702871T (pt) | Biotecido de colagénio e sua utilização | |
AU2003272187A8 (en) | Novel nanoparticles and use thereof | |
GB0220214D0 (en) | Compounds and their use | |
GB0212405D0 (en) | Composition and its therapeutic use | |
AU2003231486A8 (en) | Difructose anhydride-containing composition and use thereof | |
SG110107A1 (en) | Compound and use in treatment | |
AU2003275123A8 (en) | Composition containing ribavirin and use thereof | |
GB0227906D0 (en) | Compounds and their use | |
GB0230134D0 (en) | Compounds and their use | |
GB0230281D0 (en) | Compounds and their use | |
GB0317864D0 (en) | Compounds and their use | |
GB0323240D0 (en) | Creatine composition and use | |
GB0325239D0 (en) | Composition and use | |
GB0311164D0 (en) | Composition and use | |
GB0325241D0 (en) | Composition and use | |
GB0311163D0 (en) | Composition and use | |
GB0325238D0 (en) | Composition and use | |
GB0301401D0 (en) | Composition and use | |
GB0311167D0 (en) | Composition and use | |
GB0325237D0 (en) | Composition and use | |
GB0311166D0 (en) | Composition and use | |
GB0218253D0 (en) | Novel composition and use | |
GB0220215D0 (en) | Compounds and their use | |
AU2003255232A1 (en) | Antigiardial agents and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20201218 |